Investment Thesis
Cencora exhibits critical financial stress with negative operating cash flow of -$966.5M and free cash flow deficit of -$1.3B despite reported net income of $2.2B, indicating working capital deterioration or operational deterioration that questions sustainability. The 3.65x debt-to-equity ratio combined with deteriorating liquidity ratios (current 0.95x, quick 0.59x) and $12.4B debt burden creates significant financial vulnerability given the company's inability to generate positive operating cash to service obligations.
Strengths
- Market leadership with $164.3B revenue, indicating dominant position in pharmaceutical wholesale distribution
- Positive net income of $2.2B demonstrates operational profitability despite thin margins inherent to distribution sector
- Gross margin of 4.1% is appropriate for pharmaceutical wholesaling, suggesting scale efficiency at product level
Risks
- Negative operating cash flow of -$966.5M combined with $1.3B free cash flow deficit indicates unsustainable cash generation relative to debt obligations and capital needs
- Liquidity crisis risk with current ratio of 0.95x and quick ratio of 0.59x, suggesting inability to cover near-term liabilities with liquid resources
- Excessive leverage of 3.65x debt-to-equity paired with negative OCF and thin 1.2% operating margin provides minimal financial flexibility for disruptions or refinancing risks
Key Metrics to Watch
- Operating cash flow trajectory - must turn positive within 2-3 quarters to validate business model sustainability
- Working capital components (accounts receivable days, inventory turns, payable terms) to identify cash conversion cycle deterioration source
- Debt refinancing capacity and debt-to-EBITDA ratio given negative operating cash flow limits ability to service $12.4B debt burden
Financial Metrics
Revenue
164.3B
Net Income
2.2B
EPS (Diluted)
$11.27
Free Cash Flow
-1.3B
Total Assets
81.7B
Cash
2.2B
Profitability Ratios
Gross Margin
4.1%
Operating Margin
1.2%
Net Margin
1.3%
ROE
64.8%
ROA
2.7%
FCF Margin
-0.8%
Balance Sheet & Liquidity
Current Ratio
0.95x
Quick Ratio
0.59x
Debt/Equity
3.65x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
12.4B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T09:43:26.697357 |
Data as of: 2026-03-31 |
Powered by Claude AI